Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Clinical trial NCT01159028 · COMPLETED

Trial details

NCT number: NCT01159028
Sponsor: Bio-Path Holdings, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Adult Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome Ph1 Positive CML

Start date: 2010-06-01
Primary completion: 2017-03-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.